Payment overview · 2025
General Payments
$321.89
21 reported records · 6 companies
Healthcare provider profile · identity verified
Edward D Discoe, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · COLUMBUS, NE · NPI 1447252721
Verified facts
What the public records show
CMS Open Payments records show Edward D Discoe, M.D. received $321.89 in general payments during 2025 across 21 reported records.
Amgen Inc. accounted for 47.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $153.92 | 47.8% | 13 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $48.94 | 15.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $44.49 | 13.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.60 | 10.4% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $22.64 | 7.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.30 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $321.89 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $77.72 | 7 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $76.20 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $65.30 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $48.94 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $44.49 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $11.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 121 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
121 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
177 | 43 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 703 | 178 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 699 | 177 |
| Amlodipine Besylate | Amlodipine Besylate | 677 | 162 |
| Levothyroxine Sodium | Levothyroxine Sodium | 568 | 127 |
| Pantoprazole Sodium | Pantoprazole Sodium | 567 | 153 |
| Losartan Potassium | Losartan Potassium | 526 | 129 |
| Metoprolol Succinate | Metoprolol Succinate | 433 | 103 |
| Omeprazole | Omeprazole | 281 | 69 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 276 | 69 |
| Metformin Hcl | Metformin Hcl | 208 | 49 |
| Trazodone Hcl | Trazodone Hcl | 199 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 197 | 58 |
| Ezetimibe | Ezetimibe | 196 | 66 |
| Eliquis | Apixaban | 177 | 43 |
| Potassium Chloride | Potassium Chloride | 175 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 33 |
| Gabapentin | Gabapentin | 162 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 38 |
| Tramadol Hcl | Tramadol Hcl | 156 | 42 |
| Lisinopril | Lisinopril | 152 | 40 |
| Chlorthalidone | Chlorthalidone | 150 | 38 |
| Furosemide | Furosemide | 136 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 125 | 28 |
| Meloxicam | Meloxicam | 124 | 32 |
| Jardiance | Empagliflozin | 121 | 28 |
| Benazepril Hcl | Benazepril Hcl | 120 | 31 |
| Simvastatin | Simvastatin | 120 | 32 |
| Carvedilol | Carvedilol | 118 | 33 |
| Warfarin Sodium | Warfarin Sodium | 115 | suppressed |
| Ozempic | Semaglutide | 110 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 109 | 17 |
| Allopurinol | Allopurinol | 98 | 22 |
| Sertraline Hcl | Sertraline Hcl | 96 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 24 |
| Montelukast Sodium | Montelukast Sodium | 82 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 26 |
| Nebivolol Hcl | Nebivolol Hcl | 76 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 13 |
| Finasteride | Finasteride | 71 | 22 |
| Xarelto | Rivaroxaban | 70 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 21 |
| Repatha Sureclick | Evolocumab | 61 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 22 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 55 | 12 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 54 | 54 |
| Memantine Hcl | Memantine Hcl | 54 | suppressed |
| Prednisone | Prednisone | 54 | 13 |
| Alendronate Sodium | Alendronate Sodium | 52 | 13 |
| Famotidine | Famotidine | 52 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 51 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 15 |
| Synthroid | Levothyroxine Sodium | 51 | 11 |
| Ramipril | Ramipril | 50 | suppressed |
| Celecoxib | Celecoxib | 47 | 14 |
| Trulicity | Dulaglutide | 47 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 14 |
| Spironolactone | Spironolactone | 44 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 11 |
| Alprazolam | Alprazolam | 43 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 42 | 13 |
| Pregabalin | Pregabalin | 42 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 40 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | suppressed |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 36 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 34 | 30 |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 30 | 12 |
| Azithromycin | Azithromycin | 29 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | 12 |
| Valacyclovir | Valacyclovir Hcl | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 21 |
| Repatha Syringe | Evolocumab | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 22 |
| Amoxicillin | Amoxicillin | 23 | 16 |
| Primidone | Primidone | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 22 | suppressed |
| Plaquenil | Hydroxychloroquine Sulfate | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Praluent Pen | Alirocumab | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 14 | suppressed |
| Repaglinide | Repaglinide | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Sprintec | Norgestimate-Ethinyl Estradiol | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Np Thyroid | Thyroid,pork | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Fluorouracil | Fluorouracil | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $321.89 · 21 records | Amgen Inc. | ABRYSVO, CAPLYTA, COMIRNATY, EVENITY, FREESTYLE LIBRE 3, INSPIRE, JARDIANCE, MOUNJARO, OTEZLA, PREVNAR 20, PROLIA, REPATHA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error